Outlook Therapeutics, Inc.

NASDAQ:OTLK

5.74 (USD) • At close October 29, 2024
Bedrijfsnaam Outlook Therapeutics, Inc.
Symbool OTLK
Munteenheid USD
Prijs 5.74
Beurswaarde 135,783,144
Dividendpercentage 0%
52-weken bereik 4.61 - 13.32
Industrie Biotechnology
Sector Healthcare
CEO Mr. C. Russell Trenary III
Website https://www.outlooktherapeutics.com

An error occurred while fetching data.

Over Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Vergelijkbare Aandelen

Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation

ABUS

4.04 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

6.45 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

3.93 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

87.25 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

14.34 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

7.26 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

69.78 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.484 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)